Pelage Pharmaceuticals Raises $120 Million Series B to Boost Hair Loss Treatments
October 15, 2025
Positive Phase 2a results in androgenetic alopecia support progression into Phase 3 trials in 2026 Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, announced the